<DOC>
	<DOCNO>NCT01063660</DOCNO>
	<brief_summary>This multicenter , multinational , non-randomized , non-controlled open-label phase II trial evaluate safety efficacy treosulfan combination regimen fludarabine condition therapy prior allogeneic stem cell transplantation ( SCT ) patient AML . The aim demonstrate clinical benefit compare historical data intravenous busulfan ( BusulfexTM , BusilvexTM ) , drug far registered indication condition allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Treosulfan Based Conditioning Acute Myeloid Leukaemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients acute myeloid leukaemia ( AML ) accord WHO classification ( &gt; 20 % myeloblast peripheral blood bone marrow initial diagnosis ) &lt; 5 % myeloblast bone marrow , indicate allogeneic transplantation Availability HLAidentical sibling donor ( MRD ) HLAidentical unrelated donor ( MUD ) HLAidentity define follow marker : A , B , DRB1 , DQB1 . Target graft size ( unmanipulated ) bone marrow : 2 10 x 106 CD34+ cells/kg BW recipient &gt; 2 x 108 nucleated cells/kg BW recipient peripheral blood : 4 10 x 106 CD34+ cells/kg BW recipient Age &gt; 18 &lt; 60 year Karnofsky Index &gt; 80 % Adequate contraception female patient childbearing potential Written inform consent Therapy relate secondary AML AML ( 8 ; 21 ) ( q22 ; q22 ) CR1 Acute promyelocytic leukaemia ( 15 ; 17 ) ( q22 ; q12 ) CR1 Secondary malignancy Previous allogeneic transplantation Severe concomitant illness / medical condition ( e.g . impaired respiratory and/or cardiac function ) Known manifest malignant involvement CNS Active infectious disease HIV positivity active hepatitis infection Impaired liver function ( Bilirubin &gt; upper normal limit ; Transaminases &gt; 3.0 x upper normal limit ) Impaired renal function ( Creatinineclearance &lt; 60 ml/min ; Serum Creatinine &gt; 1.5 x upper normal limit ) . Pleural effusion ascites &gt; 1.0 L Pregnancy lactation Known hypersensitivity treosulfan and/or fludarabine Participation another experimental drug trial within 4 week day 6 Noncooperative behaviour noncompliance Psychiatric diseases condition might impair ability give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Treosulfan</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>ATG</keyword>
	<keyword>AML</keyword>
</DOC>